share_log

Cingulate | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Cingulate | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

Cingulate | POS AM：修改註冊聲明表
美股SEC公告 ·  04/01 17:05

Moomoo AI 已提取核心訊息

Cingulate Inc., a biopharmaceutical company based in Delaware, filed a post-effective amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on April 1, 2024. This amendment pertains to the registration of 5,973,000 shares of common stock underlying warrants previously issued in connection with Cingulate's public offering that closed on February 6, 2024. The shares are issuable upon the exercise of pre-funded, Series A, Series B, and placement agent warrants, with exercise prices ranging from $0.0001 to $2.50 per share. The amendment updates financial and other information from the original registration statement, which was declared effective by the SEC on February 2, 2024. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. Cingulate's common stock is listed on the Nasdaq Capital Market under the symbol 'CING', with the last reported sale price on March 28, 2024, being $1.10 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.
Cingulate Inc., a biopharmaceutical company based in Delaware, filed a post-effective amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on April 1, 2024. This amendment pertains to the registration of 5,973,000 shares of common stock underlying warrants previously issued in connection with Cingulate's public offering that closed on February 6, 2024. The shares are issuable upon the exercise of pre-funded, Series A, Series B, and placement agent warrants, with exercise prices ranging from $0.0001 to $2.50 per share. The amendment updates financial and other information from the original registration statement, which was declared effective by the SEC on February 2, 2024. No additional securities are being registered under this amendment, and all applicable registration fees were paid at the time of the original filing. Cingulate's common stock is listed on the Nasdaq Capital Market under the symbol 'CING', with the last reported sale price on March 28, 2024, being $1.10 per share. The company is identified as an 'emerging growth company' and is subject to reduced public company reporting requirements.
總部位於特拉華州的生物製藥公司Cingulate Inc. 於2024年4月1日向美國證券交易委員會（SEC）提交了其S-1表格註冊聲明的生效後修正案。該修正案涉及先前發行的與2024年2月6日結束的Cingulate公開發行相關的5,973,000股普通股標的認股權證的註冊。這些股票可在行使預先注資、A系列、B系列和配售代理認股權證後發行，行使價從每股0.0001美元到2.50美元不等。該修正案更新了原始註冊聲明中的財務和其他信息，美國證券交易委員會於2024年2月2日宣佈生效。沒有根據該修正案註冊其他證券，所有適用的註冊費均已在最初提交時支付。Cingulate的普通股在納斯達克資本市場上市，股票代碼爲 “CING”，上次公佈的銷售價格爲2024年3月28日，爲每股1.10美元。該公司被認定爲 “新興成長型公司”，上市公司報告要求有所降低。
總部位於特拉華州的生物製藥公司Cingulate Inc. 於2024年4月1日向美國證券交易委員會（SEC）提交了其S-1表格註冊聲明的生效後修正案。該修正案涉及先前發行的與2024年2月6日結束的Cingulate公開發行相關的5,973,000股普通股標的認股權證的註冊。這些股票可在行使預先注資、A系列、B系列和配售代理認股權證後發行，行使價從每股0.0001美元到2.50美元不等。該修正案更新了原始註冊聲明中的財務和其他信息，美國證券交易委員會於2024年2月2日宣佈生效。沒有根據該修正案註冊其他證券，所有適用的註冊費均已在最初提交時支付。Cingulate的普通股在納斯達克資本市場上市，股票代碼爲 “CING”，上次公佈的銷售價格爲2024年3月28日，爲每股1.10美元。該公司被認定爲 “新興成長型公司”，上市公司報告要求有所降低。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間